This piece is longer and more detailed than our usual decoded articles. That is deliberate. For a condition where treatment is essentially still trial and error, understanding what is in the pipeline and how close it actually is to clinical use matters. Some of these are years away and some are already being used off-label right now. All of them are backed by published research.
1. REGN7544 (Regeneron monoclonal antibody)
Stage: Phase 2 trial, currently recruiting
What it is: REGN7544 is a monoclonal antibody developed by Regeneron that targets NPR1, a receptor involved in regulating blood volume and cardiovascular function. When NPR1 is blocked, the body retains more fluid, which directly addresses the hypovolemic component of PoTS.
The evidence: Phase 1 results showed REGN7544 durably increased blood pressure by 5 to 10mmHg and produced biomarker changes consistent with increased plasma volume. No major safety signals were identified. The Phase 2 trial (NCT06593600) is now recruiting adults with confirmed PoTS across US and Canadian sites.
Pros: This is one of the first pharmaceutical company-led trials designed specifically for PoTS rather than repurposing an existing drug. The mechanism is targeted and biologically coherent. Phase 1 safety data is reassuring.
Cons: Results are not expected until at least 2027. The trial requires participants to stop most existing PoTS medications, which is a significant barrier for those who are managing. And targeting only the hypovolemic mechanism means it may not help patients whose PoTS is primarily neuropathic or hyperadrenergic.
2. IVIG (intravenous immunoglobulin)
Stage: Phase 2 trial completed (iSTAND), results pending
What it is: IVIG is a pooled immunoglobulin preparation derived from thousands of healthy donors. It modulates the immune system, which is relevant to PoTS given the growing evidence for autoimmune mechanisms in a subset of patients. It has been used in autoimmune neurological conditions for decades.
The evidence: A retrospective analysis of 38 patients with refractory autoimmune dysautonomias found that 84.5% improved with IVIG treatment. The iSTAND trial (NCT03919773), the first double-blind randomised controlled trial of IVIG specifically in PoTS, completed in 2023 at UT Southwestern. Results are pending publication. Multiple case series describe significant symptom reduction, with some patients able to reduce or discontinue oral medications.
Pros: Long established safety profile in other conditions. Targets the autoimmune mechanism rather than just managing symptoms. Some patients report transformative improvement.
Cons: Extremely expensive, often in the range of thousands of pounds per infusion, and rarely funded by NHS or insurance without a confirmed autoimmune diagnosis. Infusion-related side effects including headache, nausea and fatigue are common. Supply is limited as it is derived from human donors. And we do not yet know which PoTS patients are most likely to respond, likely those with confirmed autoimmune features, but this is not routinely tested for.
3. Subcutaneous immunoglobulin (SCIG)
Stage: Case series, no RCT yet
What it is: SCIG delivers the same immunoglobulin therapy as IVIG but via self-administered subcutaneous injections at home rather than hospital infusions. This is a significant practical advantage for patients who struggle to attend hospital appointments.
The evidence: A 2022 case series published in Neurology followed seven patients with severe, treatment-refractory PoTS treated with either SCIG or therapeutic plasma exchange. All seven improved, with an average 50% reduction in COMPASS-31 autonomic symptom scores and a 217% improvement in functional ability scores. Six of seven were able to reduce or stop oral medications. Five returned to work or school.
Pros: Home administration, better tolerability than IVIG in some patients, same mechanism. The functional improvement data from this case series is striking.
Cons: Seven patients. This is a very small case series and the results, however dramatic, cannot be generalised without proper controlled trials. No RCT exists. Access is extremely limited and the autoimmune evidence base for PoTS remains in development.
4. Therapeutic plasma exchange (TPE/plasmapheresis)
Stage: Case series and retrospective studies, no RCT
What it is: TPE physically removes plasma from the blood and replaces it with donor plasma or albumin solution. The idea is to remove circulating autoantibodies that may be driving autonomic dysfunction in a subset of patients.
The evidence: A 2025 paper in Cureus reviewed the evidence for TPE in PoTS and found consistent signals of benefit in patients with severe, refractory disease and suspected autoimmune involvement. The same case series cited above found significant improvements in two patients treated with plasmapheresis specifically.
Pros: Can produce rapid improvement in patients where autoantibodies are a primary driver. For severe, refractory cases it offers a mechanism that oral medications simply cannot address.
Cons: Invasive, requiring repeated sessions via central line access. Expensive. Effects may be temporary as autoantibodies regenerate, requiring ongoing treatment. Almost never available on the NHS for PoTS. Evidence remains at the case series level only.
5. Low dose naltrexone (LDN)
Stage: Pilot RCT at University of Calgary, recruiting 2026, results expected 2030
What it is: At doses of 1 to 4.5mg (a fraction of the standard opioid antagonist dose), naltrexone appears to reduce neuroinflammation via TLR4 receptor antagonism and upregulate endogenous opioid production. We decoded this in detail in a previous piece.
The evidence: A 2023 Cleveland Clinic case series showed meaningful improvement in autonomic symptom burden. A 2025 Cureus review of 29 dysautonomia patients found reduced pain and autonomic symptom scores. A 2025 systematic review in Long COVID found consistent signals for fatigue, PEM and brain fog.
Pros: Inexpensive (compared to other options), widely available off-label, well tolerated, anti-inflammatory mechanism is plausible and increasingly supported.
Cons: No RCT specifically in PoTS yet. The Calgary trial results are not expected until 2030. We do not know which patients are most likely to respond and there are patients for whom it does not work or causes sleep disturbance.
6. Semaglutide (GLP-1 receptor agonist)
Stage: Single case report showing benefit (2026), no trial
What it is: Originally a diabetes and weight management drug, semaglutide crosses the blood-brain barrier and appears to have neuroprotective and anti-inflammatory effects via GLP-1 receptors in the autonomic nervous system. We decoded this in our most recent piece.
The evidence: A 2026 case report in Clinical Autonomic Research described significant improvement in PoTS symptoms following semaglutide. The proposed mechanism involves reduction of neuroinflammation in autonomic brain regions. Contrast with tirzepatide (dual GLP-1/GIP agonist) which worsened symptoms in another patient via vasodilatory GIP receptor effects.
Pros: Already widely prescribed, relatively accessible, plausible anti-inflammatory mechanism, may benefit patients with neuroinflammatory PoTS.
Cons: Single case report. This is the weakest evidence level of anything on this list. Should not be used as a PoTS treatment without significant further research. And it may actively harm some patients depending on subtype.
7. Vagus nerve stimulation (transcutaneous auricular)
Stage: Small RCT published 2024, larger trial underway
What it is: A clip attached to the ear delivers gentle electrical stimulation to the vagus nerve via the tragus, boosting parasympathetic activity and reducing sympathetic overdrive. We decoded the ear clip trials in detail previously.
The evidence: A 2024 RCT of 57 post-COVID PoTS patients found significant reductions in postural tachycardia at one month, maintained at one year follow-up. A larger trial combining vagus nerve stimulation with slow-paced breathing is underway.
Pros: Non-invasive, drug-free, home-administered, durable effects in the published trial. The physiological rationale is well understood and directly addresses the sympathetic-parasympathetic imbalance at the core of PoTS.
Cons: 57 patients, single centre. The device used (Parasym) is commercially available but expensive and not NHS-funded for PoTS. The one-year durability finding is encouraging but needs replication in larger samples.
8. Creatine supplementation
Stage: Feasibility study 2024, small RCTs in Long COVID 2024 to 2025
What it is: Creatine replenishes phosphocreatine stores, supporting cellular energy production at the mitochondrial level. Relevant to PoTS given the evidence for mitochondrial dysfunction in post-viral dysautonomia and ME/CFS.
The evidence: A 2024 MRS brain imaging study showed measurable increases in brain creatine after 16g daily supplementation in ME/CFS patients, alongside self-reported improvements in fatigue and cognition. A 2025 trial in Long COVID found 4 weeks of 6g daily creatine significantly reduced fatigue and increased grip strength.
Pros: Inexpensive, widely available, excellent long-term safety record, directly addresses a documented mechanism.
Cons: No RCT in PoTS specifically. The evidence is in ME/CFS and Long COVID populations. The right dose, timing and duration for PoTS is unknown. Some patients report initial worsening, possibly due to metabolic shifts in an already dysregulated system.
9. Time restricted eating (TRE)
Stage: Open-label pilot study published 2025, larger trials needed
What it is: Limiting food intake to an 8 to 10 hour window daily without changing what is eaten. The proposed mechanism involves reduced inflammation, improved mitochondrial function, and better autonomic regulation via circadian rhythm entrainment.
The evidence: A 2025 Scientific Reports pilot study of 20 PoTS patients found an average 11 bpm reduction in standing heart rate, significant improvements in fatigue, GI symptoms, insomnia and exhaustion, and measurable increases in mitochondrial ATP production. The effect on heart rate was comparable in magnitude to some pharmacological interventions.
Pros: Free, low risk, no prescription required, addresses multiple mechanisms simultaneously.
Cons: 20 patients, no control group, improvements not sustained long term in other populations, and individual tolerance varies significantly particularly in patients with GI symptoms or disordered eating history.
10. Antihistamines (particularly H1 and H2 combined)
Stage: RCT published July 2026 (Lancet), earlier case reports
What it is: H1 blockers (cetirizine, loratadine, fexofenadine) and H2 blockers (famotidine) reduce histamine-mediated vasodilation and mast cell-driven inflammation. Particularly relevant in patients with MCAS overlap.
The evidence: A July 2026 Lancet Infectious Diseases RCT of nearly 800 Long COVID patients found a small but real additional benefit from famotidine-loratadine combination at 12 weeks compared to specialist care alone, though this was not sustained at 24 weeks. Earlier case reports described near-complete symptom resolution in some Long COVID patients following antihistamines, and the mechanism is coherent for patients with MCAS features.
Pros: Cheap, over the counter, excellent safety profile, immediately accessible, worth trying under clinical supervision particularly if symptoms fluctuate with food, alcohol, heat or menstrual cycle.
Cons: The Lancet benefit was modest and not sustained. Effect likely limited to patients with a histamine or mast cell component. Not a standalone treatment.
The honest summary
The PoTS treatment pipeline is more active than it has ever been, driven largely by the surge in post-COVID cases that has finally forced this condition into properly funded research. But none of the 10 treatments above has yet crossed the threshold of large-scale, properly controlled, replicated evidence specifically in PoTS. The strongest candidates are those that target the autoimmune mechanism (IVIG, SCIG, TPE) for a specific subset of patients, and those that are safe, accessible, and mechanistically coherent enough to try under clinical supervision while the larger trials complete (LDN, creatine, antihistamines, TRE).
The treatments furthest away are those in early phase trials (REGN7544). The treatments most likely to reach clinical practice first are those already used off-label with a growing evidence base.
If any of the above are relevant to your situation, the right move is always to raise them explicitly with your clinician rather than self-initiating, particularly for immunotherapies, which carry real risks and require careful patient selection.
The views and opinions expressed in Dysautonomia Decoded are my own and do not represent those of my employer or any affiliated organisation.
References
REGN7544 Phase 2 trial for POTS (PINNACLE). NCT06593600. ClinicalTrials.gov. Frontiers
Schofield JR, Chemali KR. Intravenous immunoglobulin therapy in refractory autoimmune dysautonomias: a retrospective analysis of 38 patients. American Journal of Therapeutics. 2019;26(5):e570-582.
Nelson C, Kesterson S, Schofield J, Blitshteyn S. Immunotherapy with subcutaneous immunoglobulin or plasmapheresis in patients with postural orthostatic tachycardia syndrome. Neurology. 2022.
Baykara et al. Therapeutic plasma exchange in postural tachycardia syndrome. Cureus. 2025;17(9):e91804.
Blitshteyn S, Suresh S, Lorenzi LM. Significant improvement of postural orthostatic tachycardia syndrome with semaglutide: a case report. Clinical Autonomic Research. 2026;36:315-317.
Stavrakis S, et al. Noninvasive vagus nerve stimulation in postural tachycardia syndrome. JACC: Clinical Electrophysiology. 2024;10(2):346-355.
Holwerda AM, et al. Six-week creatine supplementation in ME/CFS: a magnetic resonance spectroscopy feasibility study. Nutrients. 2024;16(19):3308.
Dzotsi M, et al. Time-restricted eating improves quality of life, heart rate, and mitochondrial function in POTS. Scientific Reports. 2025;15:34345.
Morin L, et al. Efficacy of famotidine-loratadine with specialist supportive care for fatigue in post-COVID condition. The Lancet Infectious Diseases. 2026.
iSTAND Trial. IVIG treatment study for POTS subjects. NCT03919773. ClinicalTrials.gov.
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.